Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 24 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received approval from Health Canada for Mesalamine suppositories, which are used to treat ulcerative proctitis. The approval allows Zydus to manufacture these suppositories at its facility in Changodar, Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases